Dr Lal PathLabs share price in focus: Dr Lal PathLabs on Thursday (April 30) declared its Q4 quarterly results for the financial year 2025-26. Along with the quarterly earnings, the BSE 500 company also declared a final dividend of Rs 4 per equity share for FY26.
Revenue for Q4 FY26 stood at Rs 703 crore compared to Rs 603 crore in Q4 FY25, reflecting a year-on-year increase of 16.6 per cent.
Profit for Q4 FY26 was Rs 131 crore against Rs 155 crore in Q4 FY25, registering a year-on-year decline of 15.5 per cent.
EBITDA came in at Rs 186.6 crore in Q4 FY26 versus Rs 169.4 crore in Q4 FY25, up 10.2 per cent year-on-year. EBITDA margin stood at 26.5 per cent in Q4 FY26 compared to 28.1 per cent in Q4 FY25.
Consolidated Performance Highlights: Q4 FY26
The company has recommended a final dividend of Rs 4 per share.
“Recommendation of final dividend of INR 4/- per equity share (@ 40% on a face value of INR 10/- each) for the financial year ended March 31, 2026, subject to approval of the Members of the Company at ensuing Annual General Meeting (“AGM”),” the company said in its exchange filing.
At the time of writing this report (9:02 AM), the shares of Dr LalPath Labs Ltd. were trading 0.34 per cent higher at Rs 1570.00, compared to the previous closing price of Rs 1,575.35.
(Disclaimer: The above article is meant for informational purposes only, and should not be considered as any investment advice. ET NOW DIGITAL suggests its readers/audience to consult their financial advisors before making any money related decisions.)
